bupropion has been researched along with n,n'-dodecane-1,12-diyl-bis-3-picolinium dibromide in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bardo, MT; Crooks, PA; Dwoskin, LP; Joyce, BM; Neugebauer, NM; Pivavarchyk, M; Zhang, Z; Zheng, G | 1 |
1 other study(ies) available for bupropion and n,n'-dodecane-1,12-diyl-bis-3-picolinium dibromide
Article | Year |
---|---|
Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Benzazepines; Brain; Bupropion; Dopamine; Dose-Response Relationship, Drug; Drugs, Investigational; Male; Neurons; Nicotine; Nicotinic Antagonists; Picolines; Quaternary Ammonium Compounds; Quinoxalines; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Receptors, Nicotinic; Reward; Smoking Cessation; Structure-Activity Relationship; Tobacco Use Disorder; Varenicline; Ventral Tegmental Area | 2009 |